Curcumin boosts brain delivery of HIV drug, curbing inflammation and oxidative stress

Study shows curcumin enhances antiretroviral delivery and reduces inflammation and oxidative stress in HIV, offering potential improvements in treating HIV-associated neurocognitive disorders.

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) – Biotech Investments

Biophytis / Key word(s): Miscellaneous Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) 08-Apr-2024 / 23:00 CET/CEST Biophytis launches OBA phase

April 10, 2024

Can you get satiety with GLP-1s without the nausea?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got

July 11, 2024

Sumitomo’s overactive bladder drug adds another indication

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.